Caraco Pharmaceutical Laboratories Ltd (CPD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Caraco Pharmaceutical Laboratories Ltd (CPD) trades at $5.25 with AI Score 46/100 (Grade C). Caraco Pharmaceutical Laboratories Ltd. is a healthcare company focused on developing, manufacturing, and distributing generic pharmaceutical products. Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CPD: CPD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CPD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CPD: the 1 perspectives are evenly split.
How is this calculated? →Caraco Pharmaceutical Laboratories Ltd (CPD) Healthcare & Pipeline Overview
Caraco Pharmaceutical Laboratories Ltd., operating within the Medical - Pharmaceuticals sector, focuses on developing and distributing generic drugs. The company faces competition from larger pharmaceutical firms and must navigate regulatory hurdles and pricing pressures to maintain its market position and profitability within the healthcare industry.
What Is the Investment Thesis for CPD?
Investing in Caraco Pharmaceutical Laboratories Ltd. involves considering the dynamics of the generic pharmaceutical market. The company's ability to efficiently develop, manufacture, and distribute generic drugs is a key value driver. Growth catalysts include successful product launches and expansion into new markets. However, potential risks include increased competition, regulatory challenges, and pricing pressures. Monitoring the company's financial performance, including revenue growth and profitability, is crucial for assessing its investment potential. Investors should also consider the company's ability to manage its debt and maintain a strong balance sheet. The beta of 2.14 indicates higher volatility compared to the market, suggesting a riskier investment profile.
Based on FMP financials and quantitative analysis
CPD Key Highlights
- Caraco Pharmaceutical Laboratories Ltd. operates in the generic pharmaceutical sector, focusing on developing and distributing affordable medications.
- The company's success is tied to its ability to navigate regulatory hurdles and pricing pressures within the competitive pharmaceutical landscape.
- Caraco's product portfolio consists of a range of generic drugs addressing various therapeutic areas.
- The company's geographic reach is primarily within the United States.
- With a beta of 2.14, CPD exhibits higher volatility compared to the overall market.
Who Are CPD's Competitors?
CPD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| CGEM Cullinan Therapeutics, Inc. | $17.81 | +1.02% | $1.09B | 46 |
| AIXC AIxCrypto Holdings, Inc. | $1.12 | +1.82% | $5.78M | 46 |
| LFMDP LifeMD, Inc. | $23.20 | -0.73% | $158.20M | 46 |
| ALBBY Alibaba Health Information Technology Limited | $8.00 | +0.00% | $6.45B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CPD's Key Strengths?
- Expertise in generic drug development and manufacturing.
- Established distribution network.
- Ability to source APIs at competitive prices.
- Focus on cost-effective manufacturing.
What Are CPD's Weaknesses?
- Reliance on a limited number of products.
- Vulnerability to pricing pressures from competitors.
- Dependence on third-party manufacturers for some products.
- Limited brand recognition.
What Could Drive CPD Stock Higher?
- Potential FDA approvals for new generic drug applications.
- Expansion of distribution network to reach new markets.
- Strategic partnerships to co-develop and market generic drugs.
What Are the Key Risks for CPD?
- Increased competition from other generic drug manufacturers.
- Pricing pressures from pharmacy benefit managers (PBMs).
- Changes in regulatory requirements.
- Patent challenges from branded drug manufacturers.
- Supply chain disruptions affecting API sourcing.
What Are the Growth Opportunities for CPD?
- Expansion into New Therapeutic Areas: Caraco Pharmaceutical Laboratories Ltd. can explore opportunities to expand its product portfolio into new therapeutic areas with unmet medical needs. This could involve developing and marketing generic versions of drugs used to treat conditions such as diabetes, cardiovascular diseases, or neurological disorders. The market for these drugs is substantial, with global sales in the billions of dollars. Successful expansion into these areas could significantly increase Caraco's revenue and market share. Timeline: 2-3 years.
- Strategic Partnerships and Acquisitions: Caraco Pharmaceutical Laboratories Ltd. can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other pharmaceutical companies to co-develop and market generic drugs, or acquiring smaller companies with complementary product portfolios. Such partnerships and acquisitions could provide Caraco with access to new technologies, markets, and distribution channels. Timeline: 1-2 years.
- Focus on Biosimilars: With the increasing number of biologic drugs facing patent expiration, Caraco Pharmaceutical Laboratories Ltd. can explore opportunities to develop and market biosimilars. Biosimilars are generic versions of biologic drugs, which are complex molecules derived from living organisms. The market for biosimilars is expected to grow significantly in the coming years, driven by the high cost of biologic drugs and the increasing demand for affordable healthcare. Timeline: 3-5 years.
- Geographic Expansion: Caraco Pharmaceutical Laboratories Ltd. can explore opportunities to expand its geographic reach beyond the United States. This could involve entering new markets in Europe, Asia, or Latin America. These markets offer significant growth potential, driven by increasing healthcare spending and growing demand for affordable medications. However, geographic expansion also involves navigating regulatory hurdles and cultural differences. Timeline: 2-4 years.
- Investment in Research and Development: Caraco Pharmaceutical Laboratories Ltd. can invest in research and development to develop new and improved generic drugs. This could involve developing drugs with improved formulations, delivery systems, or therapeutic profiles. Such investments could provide Caraco with a competitive advantage and allow it to capture a larger share of the generic drug market. Timeline: Ongoing.
What Opportunities Does CPD Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and acquisitions.
- Development of biosimilars.
- Geographic expansion into emerging markets.
What Threats Does CPD Face?
- Increased competition from other generic drug manufacturers.
- Pricing pressures from pharmacy benefit managers (PBMs).
- Changes in regulatory requirements.
- Patent challenges from branded drug manufacturers.
What Are CPD's Competitive Advantages?
- Regulatory expertise in navigating FDA approval processes for generic drugs.
- Established relationships with wholesale distributors and retail pharmacies.
- Efficient manufacturing and supply chain operations.
- Ability to source active pharmaceutical ingredients (APIs) at competitive prices.
What Does CPD Do?
Caraco Pharmaceutical Laboratories Ltd., headquartered in Detroit, Michigan, is a pharmaceutical company engaged in the development, sourcing, and marketing of generic pharmaceuticals. The company's history involves navigating the complexities of the generic drug market, aiming to provide cost-effective alternatives to branded medications. Caraco focuses on producing and distributing a range of generic drugs addressing various therapeutic areas. These products are sold to wholesalers, distributors, and retailers. The company's geographic reach is primarily within the United States. Caraco faces competition from other generic drug manufacturers, both large multinational corporations and smaller specialized firms. The company's success depends on its ability to efficiently manufacture and distribute its products, navigate regulatory requirements, and manage pricing pressures within the competitive pharmaceutical landscape.
What Products and Services Does CPD Offer?
- Develop generic pharmaceutical products.
- Manufacture generic drugs.
- Source active pharmaceutical ingredients (APIs).
- Market and distribute generic drugs.
- Sell products to wholesalers, distributors, and retailers.
- Ensure compliance with regulatory requirements.
- Manage supply chain and logistics.
How Does CPD Make Money?
- Develop and acquire rights to manufacture generic versions of off-patent drugs.
- Manufacture drugs in-house or through contract manufacturers.
- Distribute and sell drugs through wholesale distributors and retail pharmacies.
- Generate revenue from the sale of generic pharmaceutical products.
What Industry Does CPD Operate In?
Caraco Pharmaceutical Laboratories Ltd. operates within the medical pharmaceutical industry, a sector characterized by intense competition, stringent regulatory oversight, and constant pressure to innovate and reduce costs. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for affordable medications. Generic drug manufacturers like Caraco play a crucial role in providing cost-effective alternatives to branded drugs, contributing to healthcare accessibility. The industry is also shaped by patent expirations, which create opportunities for generic drug manufacturers to enter the market. Caraco competes with both large multinational corporations and smaller specialized firms.
Who Are CPD's Key Customers?
- Wholesale drug distributors.
- Retail pharmacy chains.
- Independent pharmacies.
- Hospitals and clinics.
Net buyingInsider Activity
The most recent 11 insider filings for Caraco Pharmaceutical Laboratories Ltd break down as 5 sales and 6 purchases. On net that is roughly 10.3M shares acquired (about $51.0M) — insiders putting money in tends to read as conviction.
CPD Valuation & Market Position
Relative to its peer group, CPD's quantitative score of 46/100 is below the peer average of 60/100.
ROE 0%Key Financial Metrics
Return on equity for Caraco Pharmaceutical Laboratories Ltd stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CPD trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Caraco Pharmaceutical Laboratories Ltd operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Detroit, US. CPD has traded publicly since 1994.
CPD Financials
Bull Case vs Bear Case
Bull Case
- Expertise in generic drug development and manufacturing.
- Established distribution network.
- Ability to source APIs at competitive prices.
- Focus on cost-effective manufacturing.
Bear Case
- Reliance on a limited number of products.
- Vulnerability to pricing pressures from competitors.
- Dependence on third-party manufacturers for some products.
- Limited brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CPD Latest News
No recent news available for CPD.
CPD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CPD.
Price Targets
Wall Street price target analysis for CPD.
CPD MoonshotScore
What does this score mean?
The MoonshotScore rates CPD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
What Investors Ask About Caraco Pharmaceutical Laboratories Ltd (CPD) — Healthcare
What does Caraco Pharmaceutical Laboratories Ltd do?
Caraco Pharmaceutical Laboratories Ltd. is a pharmaceutical company that develops, manufactures, and distributes generic drugs. The company focuses on providing affordable alternatives to branded medications, targeting a range of therapeutic areas. Caraco sells its products to wholesalers, distributors, and retailers, primarily within the United States. The company's success depends on its ability to navigate the competitive generic drug market, manage regulatory requirements, and maintain efficient manufacturing and supply chain operations.
What are the main risks for CPD?
Caraco Pharmaceutical Laboratories Ltd. faces several risks inherent to the generic pharmaceutical industry. These include intense competition from other generic drug manufacturers, which can lead to pricing pressures and reduced profitability. Regulatory changes and challenges, such as stricter FDA requirements, can also impact the company's operations and increase costs. Additionally, patent challenges from branded drug manufacturers can delay or prevent the launch of new generic drugs. Supply chain disruptions and dependence on third-party manufacturers also pose risks to the company's ability to maintain a consistent supply of products.
What are the key factors to evaluate for CPD?
Caraco Pharmaceutical Laboratories Ltd (CPD) holds an AI score of 46/100 (low). Not financial advice.
How frequently does CPD data refresh on this page?
CPD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CPD's recent stock price performance?
Caraco Pharmaceutical Laboratories Ltd (CPD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Expertise in generic drug development and manufacturing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CPD overvalued or undervalued right now?
Valuing Caraco Pharmaceutical Laboratories Ltd (CPD) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CPD?
Before investing in Caraco Pharmaceutical Laboratories Ltd (CPD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CPD to a portfolio?
Key strength of Caraco Pharmaceutical Laboratories Ltd (CPD): Expertise in generic drug development and manufacturing. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for CPD. Financial data is limited.